TNFSF11 and osteoporosis: The destructive effect of tested SPRMs into the RANK/RANKL complex makes sense to recognize this class of SPRMs as potential anti-RANKL agents with a new perspective into osteoporosis treatment for postmenopausal women and for women during breast cancer therapy that occurs with loss of bone density.